Griffithsin has antiviral activity against hepatitis C virus

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5159-5167

  Meuleman, Philip ^a,b,c   Albecka, Anna ^a,b   Belouzard, Sandrine ^a,b   Vercauteren, Koen ^c   Verhoye, Lieven ^c   Wychowski, Czeslaw ^a,b   Leroux Roels, Geert ^c   Palmer, Kenneth E ^d   Dubuisson, Jean ^a,b  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD81 ANTIGEN; LECTIN; OLIGOSACCHARIDE; RECOMBINANT GRIFFITHSIN; UNCLASSIFIED DRUG; UROKINASE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFE CYCLE; LIVER CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; VIRUS ENVELOPE; VIRUS TRANSMISSION;

ALGAL PROTEINS; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOPRECIPITATION; LECTINS; MICE; MICE, SCID; PROTEIN BINDING; VIRAL PROTEINS;

EID: 80054679007     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00633-11     Document Type: Article

References (55)

1. Baldick, C. J., et al. 2010. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 6:e1001086.
2. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642. (Pubitemid 36314658)
3. Bukh, J., et al. 2010. Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J. Infect. Dis. 201:1381-1389.
4. Bzowej, N., et al. 2011. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 17:528-538.
5. Choukhi, A., S. Ung, C. Wychowski, and J. Dubuisson. 1998. Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. J. Virol. 72:3851-3858. (Pubitemid 28188685)
6. Delgrange, D., et al. 2007. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J. Gen. Virol. 88:2495-2503. (Pubitemid 47323895)
7. Dienstag, J. L., and J. G. McHutchison. 2006. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130:231-264. (Pubitemid 43049856)
8. Dubuisson, J., et al. 1994. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J. Virol. 68:6147-6160. (Pubitemid 24294864)
9. Falkowska, E., F. Kajumo, E. Garcia, J. Reinus, and T. Dragic. 2007. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81:8072-8079. (Pubitemid 47101493)
10. Flint, M., et al. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73:6235-6244. (Pubitemid 29327798)
11. Fofana, I., et al. 2010. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139:953-964.
12. Garg, V., et al. 2011. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54:20-27.
13. Goffard, A., et al. 2005. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79:8400-8409. (Pubitemid 40853542)
14. Goffard, A., and J. Dubuisson. 2003. Glycosylation of hepatitis C virus envelope proteins. Biochimie 85:295-301. (Pubitemid 36626002)
15. Gottwein, J. M., et al. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377.
16. Goueslain, L., et al. 2010. Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J. Virol. 84:773-787.
17. Guillouche, P., and C. Feray. 2011. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment. Pharmacol. Ther. 33:163-174.
18. Helle, F., et al. 2007. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81:8101-8111. (Pubitemid 47101496)
19. Helle, F., et al. 2010. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J. Virol. 84:11905-11915.
20. Helle, F., et al. 2006. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 281:25177-25183. (Pubitemid 44401904)
21. Hunt, L. A., J. R. Etchison, and D. F. Summers. 1978. Oligosaccharide chains are trimmed during synthesis of the envelope glycoprotein of vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 75:754-758. (Pubitemid 8319452)
22. Jones, C. T., et al. 2010. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat. Biotechnol. 28:167-171.
23. Kouokam, J. C., et al. 2011. Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One 6:e22635.
24. Law, M., et al. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27.
25. Leroux-Roels, G. 2005. Development of prophylactic and therapeutic vaccines against hepatitis C virus. Expert Rev. Vaccines 4:351-371. (Pubitemid 40978697)
26. Lindenbach, B. D., et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. (Pubitemid 41033648)
27. Lindenbach, B. D., et al. 2006. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. U. S. A. 103:3805-3809. (Pubitemid 43376636)
28. Mercer, D. F., et al. 2001. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7:927-933. (Pubitemid 32756430)
29. Meuleman, P., et al. 2011. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 53:755-762.
30. Meuleman, P., et al. 2008. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48:1761-1768.
31. Meuleman, P., et al. 2005. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41:847-856. (Pubitemid 40462948)
32. Meuleman, P., P. Vanlandschoot, and G. Leroux-Roels. 2003. A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice. Biochem. Biophys. Res. Commun. 308:375-378. (Pubitemid 36937190)
33. Meuleman, P., et al. 27 September 2011, posting date. A human monoclonal antibody targeting SR-BI precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology doi:10.1002/hep.24692.
34. Meunier, J. C., et al. 2005. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl. Acad. Sci. U. S. A. 102:4560-4565.
35. Mori, T., et al. 2005. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 280:9345-9353. (Pubitemid 40409628)
36. Moulaei, T., et al. 2010. Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity. Structure 18:1104-1115.
37. Nakabayashi, H., K. Taketa, K. Miyano, T. Yamane, and J. Sato. 1982. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42:3858-3863. (Pubitemid 12054507)
38. O'Keefe, B. R., et al. 2010. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol. 84:2511-2521.
39. O'Keefe, B. R., et al. 2009. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U. S. A. 106:6099-6104.
40. Op De Beeck, A., et al. 2004. Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 78:2994-3002.
41. Pawlotsky, J. M. 2011. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 140:746-754.
42. Pietschmann, T. 2009. Virology: final entry key for hepatitis C. Nature 457:797-798.
43. Popescu, C. I., and J. Dubuisson. 2009. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol. Cell 102:63-74.
44. Scheel, T. K., et al. 2008. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. U. S. A. 105:997-1002. (Pubitemid 351282070)
45. Schiano, T. D., et al. 2006. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 12:1381-1389. (Pubitemid 44405128)
46. Syder, A. J., et al. 2011. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J. Hepatol. 54:48-55.
47. Tateno, C., et al. 2004. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165:901-912. (Pubitemid 39129297)
48. Timpe, J. M., et al. 2008. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47:17-24. (Pubitemid 351171037)
49. Vanwolleghem, T., et al. 2008. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 47:1846-1855. (Pubitemid 351945552)
50. Vanwolleghem, T., et al. 2010. Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J. Hepatol. 53:468-476.
51. Verna, E. C., and R. S. Brown, Jr. 2008. Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. Clin. Liver Dis. 12:637-659. (Pubitemid 351952468)
52. Watt, K., B. Veldt, and M. Charlton. 2009. A practical guide to the management of HCV infection following liver transplantation. Am. J. Transplant. 9:1707-1713.
53. Witteveldt, J., et al. 2009. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J. Gen. Virol. 90:48-58.
54. Ziolkowska, N. E., et al. 2006. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 14:1127-1135. (Pubitemid 44056021)
55. Ziolkowska, N. E., et al. 2007. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin. Proteins 67:661-670. (Pubitemid 46625582)